They are intended to complement a low-calorie diet and exercise as part of a weight loss or weight management plan
Retatrutide is currently investigational it has not received marketing authorisation from the MHRA, FDA, or EMA and cannot be prescribed or dispensed anywhere in the world outside of clinical trials
Severe abdominal pain Abdominal distension
Clinical trials demonstrate average weight reductions of 15-20% body weight when coupled with lifestyle modifications, positioning it as a front-runner in weight loss treatments
878 Its utility as a rapid, noninvasive biomarker for the early detection of structural colon diseases could reduce unnecessary endoscopies
Genetic variants in GLP1R, GIPR, MC4R, and FTO genes may provide context for individual response patterns, though genetics do not predict exact medication outcomes